Filtered By:
Specialty: Hematology
Condition: Anemia

This page shows you your search results in order of relevance. This is page number 5.

Order by Relevance | Date

Total 197 results found since Jan 2013.

Real-World Comparisons of Cardiovascular Events between Different Tyrosine Kinase Inhibitors Among Patients with Chronic Myeloid Leukemia
CONCLUSION: CP-CML patients treated with different TKIs (ponatinib, bosutinib, imatinib, dasatinib, and nilotinib) did not have different incidence of cardiovascular events (MACE, AOEs, VTEs) in this small cohort of real-world patients with ≥6-month of follow-up. The results were consistent among patients with prior use of one and two TKI types.DisclosuresLevy: Takeda (Millennium Pharmaceuticals, Inc.): Consultancy. Xie: STATinMED Research: Employment. Wang: STATinMED Research: Employment. Neumann: Takeda (Millennium Pharmaceuticals, Inc.): Employment. Srivastava: Takeda (Millennium Pharmaceuticals, Inc.): Employment. N...
Source: Blood - November 21, 2018 Category: Hematology Authors: Levy, M. Y., Xie, L., Wang, Y., Neumann, F., Srivastava, S., Naranjo, D., Zhang, Q., Dalal, M. Tags: 903. Outcomes Research-Non-Malignant Hematology: Poster II Source Type: research

Transcranial Doppler Screening Adherence Among Children with Sickle Cell Anemia Seen in the Emergency Department
Conclusion: Patients with SCA who present to the ED and are nonadherent to TCD screening guidelines are less likely to have had a recent hematology clinic visit. Therefore, the ED may be an important location for identifying patients lost to regular clinic follow-up in need of a TCD. An intervention that specifically targets this patient population will likely improve TCD screening rates and stroke prevention.Figure.DisclosuresNo relevant conflicts of interest to declare.
Source: Blood - November 21, 2018 Category: Hematology Authors: Weisman, J. K., Diamond, C., Kappa, S., Nickel, R. S. Tags: 903. Outcomes Research-Non-Malignant Hematology: Poster II Source Type: research

Characterizing a Population with Severe Manifestations of Sickle Cell Disease Using U.S. Real-World Evidence
ConclusionsBased on this contemporary real-world evidence from the U.S. setting, a substantial proportion of patients with SCD experience a diverse set of severely debilitating complications of the disease, as well as other co-morbidities associated with the disease. The high rate of comorbidities across all age groups and overrepresentation of patients younger than 30 years of age (relative to age distribution of general U.S. population) indicate that patients with SCD still experience significant morbidity and early mortality with current standard medical care. Given the notable heterogeneity of the clinical manifestatio...
Source: Blood - November 21, 2018 Category: Hematology Authors: Paramore, C., Kong, A., Minegishi, S., Shi, W. Tags: 903. Outcomes Research-Non-Malignant Hematology: Poster III Source Type: research

Haptoglobin, alpha‐thalassaemia and glucose‐6‐phosphate dehydrogenase polymorphisms and risk of abnormal transcranial Doppler among patients with sickle cell anaemia in Tanzania
Summary Transcranial Doppler ultrasonography measures cerebral blood flow velocity (CBFv) of basal intracranial vessels and is used clinically to detect stroke risk in children with sickle cell anaemia (SCA). Co‐inheritance in SCA of alpha‐thalassaemia and glucose‐6‐phosphate dehydrogenase (G6PD) polymorphisms is reported to associate with high CBFv and/or risk of stroke. The effect of a common functional polymorphism of haptoglobin (HP) is unknown. We investigated the effect of co‐inheritance of these polymorphisms on CBFv in 601 stroke‐free Tanzanian SCA patients aged <24 years. Homozygosity for alpha‐t...
Source: British Journal of Haematology - February 22, 2014 Category: Hematology Authors: Sharon E. Cox, Julie Makani, Deogratias Soka, Veline S. L'Esperence, Edward Kija, Paula Dominguez‐Salas, Charles R. J. Newton, Anthony A. Birch, Andrew M. Prentice, Fenella J. Kirkham Tags: Research Paper Source Type: research

Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload
Summary Serial phlebotomy was performed on sixty children with sickle cell anaemia, stroke and transfusional iron overload randomized to hydroxycarbamide in the Stroke With Transfusions Changing to Hydroxyurea trial. There were 927 phlebotomy procedures with only 33 adverse events, all of which were grade 2. Among 23 children completing 30 months of study treatment, the net iron balance was favourable (−8·7 mg Fe/kg) with significant decrease in ferritin, although liver iron concentration remained unchanged. Therapeutic phlebotomy was safe and well‐tolerated, with net iron removal in most children who completed 30...
Source: British Journal of Haematology - January 22, 2015 Category: Hematology Authors: Banu Aygun, Nicole A. Mortier, Karen Kesler, Alexandre Lockhart, William H. Schultz, Alan R. Cohen, Ofelia Alvarez, Zora R. Rogers, Janet L. Kwiatkowski, Scott T. Miller, Pamela Sylvestre, Rathi Iyer, Peter A. Lane, Russell E. Ware, Tags: Short Report Source Type: research

Anemia predicts thromboembolic events, bleeding complications and mortality in patients with atrial fibrillation: Insights form the RE‐LY trial
ConclusionsAnemia is associated with a raised risk of thromboembolic events, bleeding complications and mortality in anticoagulated patients with AF. These findings suggest that patients with anemia should be monitored closely during all types of anticoagulant treatment.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - February 1, 2015 Category: Hematology Authors: B. Daan Westenbrink, Marco Alings, Stuart J. Connolly, John Eikelboom, Michael D. Ezekowitz, Jonas Oldgren, Sean Yang, Janice Pongue, Salim Yusuf, Lars Wallentin, W.H. Gilst Tags: Original Article ‐ Cardiovascular Medicine Source Type: research

Anemia predicts thromboembolic events, bleeding complications and mortality in patients with atrial fibrillation: Insights form the RE-LY trial.
CONCLUSIONS: Anemia is associated with a raised risk of thromboembolic events, bleeding complications and mortality in anticoagulated patients with AF. These findings suggest that patients with anemia should be monitored closely during all types of anticoagulant treatment. This article is protected by copyright. All rights reserved. PMID: 25683276 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - February 13, 2015 Category: Hematology Authors: Westenbrink BD, Alings M, Connolly SJ, Eikelboom J, Ezekowitz MD, Oldgren J, Yang S, Pongue J, Yusuf S, Wallentin L, van Gilst WH Tags: J Thromb Haemost Source Type: research

G6PD deficiency and absence of α‐thalassemia increase the risk for cerebral vasculopathy in children with sickle cell anemia
This article is protected by copyright. All rights reserved.
Source: European Journal of Haematology - June 13, 2015 Category: Hematology Authors: Philippe Joly, Nathalie Garnier, Kamila Kebaili, Céline Renoux, Arthur Dony, Nathalie Cheikh, Cécile Renard, Antony Ceraulo, Daniela Cuzzubbo, Corinne Pondarré, Cyril Martin, Vincent Pialoux, Alain Francina, Yves Bertrand, Philippe Connes Tags: Original Article Source Type: research

Transfusion therapy for sickle cell disease
The clinical presentations of sickle cell disease include acute pain, acute chest syndrome, stroke and acute anaemia and blood transfusion therapy can be used effectively in the emergency setting for the treatment of many of these complications. Long‐term blood transfusion therapy is also used for the prevention of disease complications with most evidence for its use in primary stroke prevention. Transfusion can be given as a simple or top‐up transfusion or as an exchange transfusion and donor red cells should be haemoglobin S negative and as a minimum matched for ABO, full Rh and Kell type. Repeated transfusions lead ...
Source: ISBT Science Series - January 29, 2016 Category: Hematology Authors: J. Howard, S. E. Robinson Tags: Invited Review Source Type: research

Long-term treatment follow-up of children with sickle cell disease monitored with abnormal transcranial Doppler velocities
We present the long-term follow-up of SCA children from the Créteil newborn cohort (1992-2012) detected at risk by TCD and placed on chronic transfusions. Patients with normalized velocities and no stenosis were treated with hydroxyurea, known to decrease anemia and hemolytic rate. Trimestrial Doppler was performed and transfusions restarted immediately in the case of reversion to abnormal velocities. Patients with a genoidentical donor underwent transplant. Abnormal time-averaged maximum mean velocities (TAMMV) ≥200 cm/s were detected in 92 SCA children at a mean age of 3.7 years (range, 1.3-8.3 years). No strok...
Source: Blood - April 6, 2016 Category: Hematology Authors: Bernaudin, F., Verlhac, S., Arnaud, C., Kamdem, A., Hau, I., Leveille, E., Vasile, M., Kasbi, F., Madhi, F., Fourmaux, C., Biscardi, S., Gluckman, E., Socie, G., Dalle, J.-H., Epaud, R., Pondarre, C. Tags: Pediatric Hematology, Sickle Cell Disease, Free Research Articles, Red Cells, Iron, and Erythropoiesis, Clinical Trials and Observations Source Type: research

Hemorheological alterations in sickle cell anemia and their clinical consequences - the role of genetic modulators.
Abstract Sickle cell anemia (SCA) is an autosomal recessive disease caused by the HBB:c.20A>T mutation that leads to hemoglobin S synthesis. The disease presents with high clinical heterogeneity characterized by chronic hemolysis, recurrent episodes of vaso-oclusion and infection. This work aimed to characterize by in silico studies some genetic modulators of severe hemolysis and stroke risk in children with SCA, and understand their consequences at the hemorheological level.Association studies were performed between hemolysis biomarkers as well as the degree of cerebral vasculopathy and the inheritance of seve...
Source: Clinical Hemorheology and Microcirculation - November 3, 2016 Category: Hematology Authors: Silva M, Vargas S, Coelho A, Dias A, Ferreira T, Morais A, Maia R, Kjöllerström P, Lavinha J, Faustino P Tags: Clin Hemorheol Microcirc Source Type: research

Prevention of central nervous system sequelae in sickle cell disease without evidence from randomized controlled trials: the case for a team-based learning collaborative.
Authors: DeBaun MR, King AA Abstract Since 1998, the National Institutes of Health has funded 5 randomized controlled trials (RCTs) for primary and secondary prevention of strokes in children with sickle cell anemia (SCA). In a systematic fashion, these trials have significantly advanced the care of children with SCA. In the absence of an RCT, clinicians are often compelled to make decisions at the bedside, based on experience, observational studies, and principles of hematology. We will provide an initial example that describes how a team-based, learning collaborative developed a multisite standard care protocol w...
Source: Hematology ASH Education Program - December 4, 2016 Category: Hematology Tags: Hematology Am Soc Hematol Educ Program Source Type: research

A systematic review of the literature for severity predictors in children with sickle cell anemia
Publication date: Available online 2 February 2017 Source:Blood Cells, Molecules, and Diseases Author(s): Emily Riehm Meier, Ross M. Fasano, Paul R. Levett All patients with HbSS (SCA) share the same genetic mutation but the clinical phenotype is variable and difficult to predict early in life. A reliable severity predictor would be invaluable toward directing therapeutic decisions in those patients at highest risk of SCA complications. A search of PubMed, Cochrane Clinical Trials Register, and Scopus was performed to determine which SCA severity predictors have been validated in pediatric patients. The full text of 94 of...
Source: Blood Cells, Molecules, and Diseases - February 2, 2017 Category: Hematology Source Type: research

A systematic review of the literature for severity predictors in children with sickle cell anemia.
Abstract All patients with HbSS (SCA) share the same genetic mutation but the clinical phenotype is variable and difficult to predict early in life. A reliable severity predictor would be invaluable toward directing therapeutic decisions in those patients at highest risk of SCA complications. A search of PubMed, Cochrane Clinical Trials Register, and Scopus was performed to determine which SCA severity predictors have been validated in pediatric patients. The full text of 94 of the 590 references identified was reviewed based on the title/abstract. Fifty-four articles were included in the analysis. Alpha globin ge...
Source: Blood Cells, Molecules and Diseases - February 1, 2017 Category: Hematology Authors: Meier ER, Fasano RM, Levett PR Tags: Blood Cells Mol Dis Source Type: research

Foetal haemoglobin and disease severity in nigerian children with sickle cell anaemia.
Conclusion: Children with SCA who had moderate disease and those with history of life threatening complications such as stroke and acute chest syndrome had significantly low HbF. Therefore it is recommended that facilities for early quantification of foetal haemoglobin and HbF inducement be made available in order to reduce the morbidity and mortality among these children.
Source: Mediterranean Journal of Hematology and Infectious Diseases - October 25, 2017 Category: Hematology Source Type: research